Cancer patients do not die of cancer itself but of wasting and cortisone (hormonal disturbance).
Original statement
كل عانين السرطان ما بيموتو بسرطان اصلا بيموتوا بايه بكشكش يا هزال الكورتيزون
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Cancer patients do not die of cancer itself but of wasting and cortisone (hormonal disturbance).
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- السرطان ١ (Open source)
- Published
- 26 January 2025
- Timestamp
- 0:44:54 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- Population concerned
Patients with advanced cancer
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Death is due to wasting/cortisone, not cancer.
2. What is demonstrably correct?
Cachexia (wasting) is a frequent, serious feature of advanced cancer and can be a proximal cause of death, for example through loss of heart or breathing muscle (I-CAN-108). Glucocorticoid signalling contributes to tumour-induced muscle wasting in mice (I-CAN-109), and prolonged corticosteroid medication causes rapid muscle loss in cachectic patients (I-SRC-108).
3. What is wrong or exaggerated?
Cachexia is driven by the tumour (cytokines, reduced intake, metabolic changes) and is not fully reversible by nutrition (I-CAN-06, I-CAN-108); it often improves when anticancer treatment is effective (I-SRC-108). It is therefore part of dying from cancer, not an alternative to it. In a hospital series the underlying cause of death was cancer-related in 83% (I-CAN-110).
4. What remains unclear?
The share of cancer deaths in which cachexia is the leading clinical feature varies by cancer type and is not quantified in the source reviewed (I-CAN-06).
5. Which studies support it?
Partly: cachexia is common and can be a proximal cause of death (I-CAN-108); glucocorticoids contribute to muscle wasting (I-CAN-109, I-SRC-108).
6. Which studies contradict it?
I-CAN-06, I-SRC-108, I-CAN-108, I-CAN-110.
7. What applies to Germany and Europe?
Not region-specific; the same physiology and evidence apply.
8. What is known about Egypt?
Not region-specific; the same physiology and evidence apply.
9. What practical conclusion is appropriate?
Unintended weight loss in cancer needs prompt medical and dietetic attention.
Assessment details
- Rationale for certainty of evidence
Moderate: an ESMO guideline (I-SRC-108), an international consensus (I-CAN-06) and a 2024 review (I-CAN-108) consistently describe cachexia as tumour-driven and improving with effective anticancer treatment; cause-of-death data show cancer as the underlying cause in most deaths (I-CAN-110). Quantitative data on the share of deaths dominated by cachexia are lacking.
- Source quality
Machine transcript.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).
Research question: In patients with advanced cancer, is death caused by wasting and hormonal (cortisol/cortisone) disturbance independently of the cancer, or are these part of the cancer process?
Research question in detail (PECO)
- Population
- Patients with advanced cancer
- Intervention or exposure
- Cachexia; glucocorticoid (endogenous or therapeutic) exposure
- Comparison
- Cancer progression and organ failure
- Geographic scope
- universal biology
- Outcomes
- Cause of death
- Muscle wasting
- Response of cachexia to anticancer treatment
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Weight loss and survival in bowel and pancreatic cancer
Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510 Systematic reviewabstract checkednewly addedSystematic review: cachexia/weight loss associated with poorer survival in colorectal and pancreatic cancer.
- Actual result
- Significant association in 16 of 23 multivariate studies
- Methodological quality
- moderate (systematic review of observational studies; Pfizer-funded)
- Relevance
- direct for 'wasting matters'
- Limitations
- Association may reflect cancer severity.
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 Guideline / position statementabstract checkednewly addedESMO guideline: prolonged corticosteroid therapy causes rapid muscle loss and worsens cachexia.
- Actual result
- Corticosteroids limited to 2-3 weeks
- Methodological quality
- high (guideline)
- Relevance
- direct for the 'cortisone' kernel
- Limitations
- Concerns medication, not a cause of death replacing cancer.
Why do people with cancer die?
Boire A et al.. Nat Rev Cancer 2024 · PMID 38898221 · DOI 10.1038/s41568-024-00708-4 Narrative reviewabstract checkednewly addedReview: cachexia is a frequent proximal contributor to death and does not correlate with tumour volume.
- Actual result
- Acute events may cause up to half of deaths; cachexia multifactorial
- Methodological quality
- moderate (narrative review)
- Relevance
- direct
- Limitations
- Not systematic.
What speaks against the claim?
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092 Guideline / position statementabstract checkednewly addedESMO: effective anticancer treatment often improves cachexia; ineffective treatment aggravates it.
- Actual result
- Guideline statement
- Methodological quality
- high
- Relevance
- direct: wasting is part of the cancer process
- Limitations
- Expert-level evidence.
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7 Guideline / position statementabstract checkedInternational consensus defines cachexia as tumour-driven and not fully reversible by nutrition.
- Actual result
- Consensus definition
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- Consensus.
What cancer inpatients died of in an Indian hospital
Doshi A et al.. Public Health Action 2026 · PMID 42830814 · DOI 10.5588/pha.26.0040 Cohort studyabstract checkednewly addedCauses of inpatient cancer deaths in India.
- Actual result
- Underlying cause cancer-related 83%; immediate: progression 57%, organ failure 21%, sepsis 15%
- Methodological quality
- low (single centre)
- Relevance
- direct
- Limitations
- No cachexia category.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Wasting and hormonal-inflammatory changes are real mechanisms through which cancer kills; they are caused by the tumour and often improve when cancer treatment works. Separating them from 'dying of cancer' is a false dichotomy.
Why some studies weigh more
Guideline and consensus statements (I-SRC-108, I-CAN-06) and mechanistic reviews weigh more than single-centre data; animal data only explain mechanism.
Is a causal relationship established? Yes, established Tumour-derived cytokines and signals cause cachexia (I-CAN-108, I-CAN-109); treating the tumour improves it (I-SRC-108).
Remaining uncertainty
Exact share of cancer deaths in which cachexia is the leading proximal cause is unknown.
Justified conclusion
The claim overinterprets a real phenomenon: patients do die with wasting, and glucocorticoids contribute, but this is part of dying from cancer.
Why do studies seem to disagree?
No true conflict: studies emphasising cachexia and hormonal mechanisms (I-CAN-108, I-CAN-109) and studies emphasising cancer progression (I-CAN-110) describe the same causal chain at different levels.
Does this depend on the country?
- General biological effects
- Universal human biology; applies in Egypt, Germany and elsewhere.
- Eating habits
- Not decisive for this claim.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant.
- National production conditions
- Not relevant.
- Legal rules
- Not relevant.
- Actual monitoring data
- Not applicable.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Recount of proportions – 57%/21%/15% of 474 deaths = about 270/100/71; cachexia not recorded separately. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Cachexia as a cancer-driven process vs independent cause of death
- Starting level
- low (observational studies)
- Reasons for downgrading
- imprecision (no quantitative cause-of-death data on cachexia)
- Reasons for upgrading
- consistency of mechanistic and guideline evidence
- biological gradient (improves with effective treatment)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ESMO: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines (PMID 34144781) (2021) · Original publication
Effective anticancer treatment often improves cachexia; nutritional support is recommended for patients receiving anticancer treatment; corticosteroids only for 2-3 weeks because prolonged use causes muscle loss and insulin resistance. - ESPEN: ESPEN guidelines on nutrition in cancer patients (I-INTA-09, PMID 27637832) (2017) · Original publication
Screen all cancer patients for malnutrition and meet energy and protein needs, except at end of life (as recorded for I-INTA-09; abstract).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | TITLE:"cancer cachexia" AND (TITLE:"ESMO" OR TITLE:"ASCO guideline") | guidelines | 7 | |
| Europe PMC | 26 October 2026 | (autopsy OR "post-mortem" OR "immediate cause of death" OR "causes of death") AND ("cancer patients" OR "patients with cancer" OR "solid tumors") AND (cachexia OR infection OR "organ failure") | both directions | 14713 | |
| Europe PMC | 26 October 2026 | (glucocorticoid OR cortisol OR corticosterone) AND ("cancer cachexia") AND (muscle wasting) AND (TITLE:glucocorticoid OR TITLE:cortisol OR TITLE:corticosterone) | supporting evidence | 13 | |
| Europe PMC | 26 October 2026 | (Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady") | both directions | 377 | |
| PubMed | 26 October 2026 | (cachexia[ti]) AND ("cause of death"[tiab] OR "causes of death"[tiab] OR mortality[ti]) | supporting evidence | 93 | |
| PubMed | 26 October 2026 | ("causes of death"[ti] OR "cause of death"[ti]) AND (cancer[ti] OR neoplasms[ti]) AND (autopsy[tiab] OR "death certificate"[tiab]) | contradicting evidence | 39 |
Open questions
Systematic autopsy data on proximal causes of cancer death.
How deeply was this checked?
6 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (low)
- 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly false (low) → Mostly false (moderate)
Certainty raised from low to moderate: the ESMO guideline (I-SRC-108), a 2024 review of causes of cancer death (I-CAN-108) and cause-of-death data (I-CAN-110) consistently show that cachexia is tumour-driven and responds to effective cancer treatment. The new evidence also supports a kernel (glucocorticoid signalling and prolonged corticosteroid therapy contribute to muscle loss), so the verdict stays “Mostly false”.
New sources: I-SRC-108 I-CAN-108 I-CAN-109 I-CAN-110 I-CAN-126
In plain language
Dr. Diaa said cancer patients die of wasting and cortisone, not of the cancer. Wasting is indeed common in advanced cancer, and long use of steroid medicines can make muscle loss worse. But the wasting itself is caused by the cancer, which changes appetite and metabolism, and it often improves when cancer treatment works. So wasting is one way cancer kills, not a separate cause.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (3)
-
Cancer wasting is caused by the cancer itself
Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7Guideline / position statementindependent cross-checkabstract checkedExperts define cachexia as muscle loss driven by the tumour's effects on metabolism and appetite, not fully reversible by food.
Cachexia is part of the cancer process
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Define cachexia.
- How was the study done?
Delphi consensus.
- How many people, animals or samples were studied?
Experts.
- What was actually found?
Definition.
- What do the results mean in everyday life?
Weight loss in cancer needs medical attention.
- What are the study's limitations?
Consensus.
- What does it say about Elawady's specific claim?
Contradicts 'not dying of cancer'.
- Do the results apply to Germany and Europe?
High.
-
ESMO guideline on weight loss in cancer
Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092Guideline / position statementindependent cross-checkabstract checkedCancer patients on treatment should be screened for malnutrition and get at least 25-30 kcal per kg body weight per day.
Cachexia is cancer-driven and improves with effective anticancer treatment; prolonged corticosteroids worsen muscle loss (partial kernel)
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Guide cachexia care
- How was the study done?
Guideline
- How many people, animals or samples were studied?
not applicable
- What was actually found?
Screen and feed adequately; escalate nutrition when intake is low
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Cancer patients need enough food, not fasting regimes
- What are the study's limitations?
Low evidence levels for some points
- What does it say about Elawady's specific claim?
Contradicts fasting as treatment
- Do the results apply to Germany and Europe?
High
-
What cancer inpatients died of in an Indian hospital
Doshi A et al.. Public Health Action 2026 · PMID 42830814 · DOI 10.5588/pha.26.0040Cohort studyindependent cross-checkabstract checkedMost deaths were due to cancer progression (57%), organ failure (21%) or sepsis (15%).
Underlying cause of death cancer-related in 83%
Does the study support the specific claim? No · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Describe causes of death.
- How was the study done?
Hospital record review.
- How many people, animals or samples were studied?
474 deaths.
- What was actually found?
Cancer progression dominant.
- How large was the observed effect?
57% immediate; 83% underlying.
- What do the results mean in everyday life?
People with cancer mostly die from the cancer and its complications.
- What are the study's limitations?
Single centre; no cachexia category.
- What does it say about Elawady's specific claim?
Contradicts the claim.
- Do the results apply to Germany and Europe?
Low-moderate.
- What can explicitly not be concluded from this study?
Role of cachexia.
No study in this group is marked as key.
Studies with mixed or unclear results (3)
-
Why do people with cancer die?
Boire A et al.. Nat Rev Cancer 2024 · PMID 38898221 · DOI 10.1038/s41568-024-00708-4Narrative reviewindependent cross-checkabstract checked★ key studyDeath in cancer usually results from several organ problems caused by the cancer, including wasting; tumour size alone does not explain it.
Cachexia is a real proximal mechanism, but it is caused by the cancer
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review causes of death in cancer.
- How was the study done?
Narrative review.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Many interlinked causes, including cachexia.
- How large was the observed effect?
Acute events may cause up to half of deaths.
- What do the results mean in everyday life?
Wasting is one way cancer kills.
- What are the study's limitations?
Not systematic.
- What does it say about Elawady's specific claim?
Partly right that tumour mass is not everything; wrong that cancer is not the cause.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Precise proportions.
-
Stress hormones help drive cancer wasting in mice
Braun TP et al.. FASEB J 2013 · PMID 23733748 · DOI 10.1096/fj.13-230375Animal studyindependent cross-checkabstract checkedMice lacking glucocorticoid receptors in muscle lost 77% less muscle when they had tumours.
Glucocorticoid signalling mediates tumour-induced muscle wasting in mice
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test role of glucocorticoids in cachexia.
- How was the study done?
Knockout mouse experiments.
- How many people, animals or samples were studied?
Mice.
- What was actually found?
Glucocorticoid signalling needed for much of the wasting.
- How large was the observed effect?
77% less atrophy.
- What do the results mean in everyday life?
Hormones are part of how cancer causes wasting.
- What are the study's limitations?
Mouse data.
- What does it say about Elawady's specific claim?
Partly supports the hormonal idea, not the conclusion.
- Do the results apply to Germany and Europe?
Low.
- What can explicitly not be concluded from this study?
Effects in humans.
-
Weight loss and survival in bowel and pancreatic cancer
Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510Systematic reviewindependent cross-checkabstract checkedIn about two-thirds of studies, cancer patients with wasting or weight loss lived shorter.
Cachexia associated with poorer survival in ~2/3 of studies
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link cachexia and survival.
- How was the study done?
Systematic review.
- How many people, animals or samples were studied?
26 studies.
- What was actually found?
Wasting linked to shorter survival.
- How large was the observed effect?
16 of 23 multivariate studies.
- What do the results mean in everyday life?
Weight loss in cancer needs attention.
- What are the study's limitations?
Observational; Pfizer funding.
- What does it say about Elawady's specific claim?
Supports the kernel only.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That wasting rather than cancer kills.
No study in this group is marked as key.
Regional context
Germany / EU
Not region-specific; the same physiology and evidence apply.
Egypt
Not region-specific; the same physiology and evidence apply.
What applies in my country?
General scientific assessment
Mostly false Wasting and stress hormones are part of how cancer kills; they are caused by the cancer and do not mean patients die of something other than cancer.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Definition and classification of cancer cachexia: an international consensus.. Fearon K et al.. Lancet Oncol 2011 · PMID 21296615 · DOI 10.1016/S1470-2045(10)70218-7
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆.. Arends J et al. (ESMO Guidelines Committee). ESMO Open 2021 · PMID 34144781 · DOI 10.1016/j.esmoop.2021.100092
- Why do cancer patients die? A decade of experience on trends, profile, causes, and timing of deaths in India.. Doshi A et al.. Public Health Action 2026 · PMID 42830814 · DOI 10.5588/pha.26.0040
- Why do patients with cancer die?. Boire A et al.. Nat Rev Cancer 2024 · PMID 38898221 · DOI 10.1038/s41568-024-00708-4
- Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.. Braun TP et al.. FASEB J 2013 · PMID 23733748 · DOI 10.1096/fj.13-230375
- The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.. Dunne RF et al.. J Cachexia Sarcopenia Muscle 2024 · PMID 39095951 · DOI 10.1002/jcsm.13510